Sapace purchased 300 million Qiangshen pharmaceutical five years ago and plans to sell it at a reserve price of 195 million yuan

category:Finance
 Sapace purchased 300 million Qiangshen pharmaceutical five years ago and plans to sell it at a reserve price of 195 million yuan


Established in 2014, Qiangshen Pharmaceutical Co., Ltd. was formerly Jilin Qiangshen Pharmaceutical Co., Ltd. its main products are Sizi Tianjing capsule and compound Gaoshan Rhodiola oral liquid. In November 2015, sapace signed an equity transfer agreement with Jilin Dongfeng Pharmaceutical Co., Ltd. (hereinafter referred to as Dongfeng pharmaceutical), and both parties agreed that the transfer price of 100% equity of Qiangshen pharmaceutical was RMB 346 million.

After that, sapace issued 13.87 million shares of common stock (a share) to six specific objects. After deducting the issuance expenses, the actual net amount raised was 480 million yuan, and 346 million yuan was used to acquire 100% equity of Qiangshen pharmaceutical, and the rest was used for the new production workshop and warehouse project of traditional Chinese medicine extraction.

At that time, with the integration of traditional Chinese medicine and Western medicine products, the company was able to make more profits in the two fields. According to the equity transfer agreement, Dongfeng Pharmaceutical Co., Ltd. has promised to strengthen the pharmaceutical industry. The net profit of assessment in 2016, 2017 and 2018 is no less than 10 million yuan, 30 million yuan and 50 million yuan respectively.

However, Qiangshen Pharmaceutical Co., Ltd. did not fulfill the performance commitment. Its actual performance from 2016 to 2018 was 1253900 yuan, 10284200 yuan and - 802.3100 yuan respectively.

Dongfeng Pharmaceutical Co., Ltd. and Liu Xianbin need to pay performance compensation to sapace. Sapace reported in the half year of 2020 that the relevant payment and interest have been paid in full.

In the first eight months of this year, Qiangshen pharmaceutical achieved a revenue of 7.33 million yuan and a net profit of about 26.42 million yuan, which has become the performance burden of the company.

Sapace is in the shadow of magic medicine

The companys own performance is under pressure. In the first three quarters of this year, the actual operating revenue was 240 million yuan, a year-on-year decrease of 40.61%. The net profit attributable to the parent company was a loss of 28.06 million yuan, down 171.65% year on year.

On December 2, 2017, the article selling 750 million brain washing drugs a year, please let go of the old Chinese people made sapace fall into a miracle drug storm. The article questioned the advertising and efficacy of sapace eye drops, which caused great repercussions. After that, sapace issued a clarification notice, saying: the company believes that 0.5% benzaldehyde lysine eye drops have certain effects on delaying the development of senile cataract and improving or maintaining eyesight, and it is a safe and effective anti cataract drug. However, stock prices continued to fall. Now, three years later, sapace has not completely walked out of the shadow of Shenyao storm in 2017. On the afternoon of November 23, sapace released an announcement saying: due to the reports of sapaces we media events, sapaces brand reputation has been negatively affected, and the relevant marketing plan has not been implemented as planned, resulting in a sharp drop in the sales volume of Chinese patent medicine products. In addition, due to the impact of the new crown epidemic and the limitation of subsequent sales expenses, the future annual forecast of (Qiangshen pharmaceutical) Co., Ltd It will continue to lose money. The consistency evaluation of benadrysine eye drops launched by sapace in 2016 is regarded as a card for self justification, but it is advancing slowly. Source: Daily Economic News Author: Zeng Jian intern reporter, Tan Zhongkui, editor in charge: Wang Xiaowu_ NF

On December 2, 2017, the article selling 750 million brain washing drugs a year, please let go of the old Chinese people made sapace fall into a miracle drug storm. The article questioned the advertising and efficacy of sapace eye drops, which caused great repercussions. After that, sapace issued a clarification notice, saying: the company believes that 0.5% benzaldehyde lysine eye drops have certain effects on delaying the development of senile cataract and improving or maintaining eyesight, and it is a safe and effective anti cataract drug. However, stock prices continued to fall.

Now, three years later, sapace has not completely walked out of the shadow of Shenyao storm in 2017. On the afternoon of November 23, sapace released an announcement saying: due to the reports of sapaces we media events, sapaces brand reputation has been negatively affected, and the relevant marketing plan has not been implemented as planned, resulting in a sharp drop in the sales volume of Chinese patent medicine products. In addition, due to the impact of the new crown epidemic and the limitation of subsequent sales expenses, the future annual forecast of (Qiangshen pharmaceutical) Co., Ltd It will continue to lose money.

The consistency evaluation of benadrysine eye drops launched by sapace in 2016 is regarded as a card for self justification, but it is advancing slowly.